Metastatic renal cell carcinoma without evidence of a renal primary
International Urology and Nephrology, ISSN: 1573-2584, Vol: 48, Issue: 1, Page: 73-77
2016
- 11Citations
- 16Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes11
- 11
- CrossRef6
- Captures16
- Readers16
- 16
Article Description
Purpose: Metastatic renal cell carcinoma (RCC), without an identified kidney primary, has been reported rarely. We report a patient with RCC metastatic to bilateral adrenal glands and liver, without an apparent renal primary. We detail the immunohistochemical and molecular studies employed to substantiate the diagnosis of RCC and direct therapy. Methods: Histopathologic findings were correlated with imaging data and supplemented by a panel of immunohistochemical stains, as well as tumor sequence analysis. Results: Despite the presence of bilateral adrenal masses and lack of tumor within kidney parenchyma, the diagnosis of RCC was substantiated by immunohistochemistry (RCC+/PAX2+/PAX8+/Melan-A−/SF-1− among others) and molecular genetic analysis, harboring mutations in VHL,TP53, KDM5C, and PBRM1. After debulking surgery, based on the diagnosis of RCC and the molecular profile, the patient was treated with a tyrosine kinase inhibitor (sunitinib), resulting in stablilization of disease. Conclusions: This case illustrates the role of mutational analysis in carcinomas with rare or unusual presentations, such as metastatic RCC without a renal primary.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84953639739&origin=inward; http://dx.doi.org/10.1007/s11255-015-1145-3; http://www.ncbi.nlm.nih.gov/pubmed/26527083; http://link.springer.com/10.1007/s11255-015-1145-3; https://dx.doi.org/10.1007/s11255-015-1145-3; https://link.springer.com/article/10.1007/s11255-015-1145-3; http://link.springer.com/article/10.1007/s11255-015-1145-3/fulltext.html; https://link.springer.com/content/pdf/10.1007%2Fs11255-015-1145-3.pdf; http://link.springer.com/article/10.1007%2Fs11255-015-1145-3; http://link.springer.com/content/pdf/10.1007/s11255-015-1145-3; http://link.springer.com/content/pdf/10.1007/s11255-015-1145-3.pdf; https://ohsu.pure.elsevier.com/en/publications/0a127248-7485-4b75-959a-2364a169eff9
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know